{"schema_version":"secwatch.filing_event.v1","accession":"0000896264-24-000138","form_type":"8-K","ticker":"USNA","cik":"0000896264","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.366680+00:00","generated_at":"2026-06-03T05:14:23.859839+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"USANA Q1 net sales $228M (-8% YoY), EPS $0.86, reaffirms FY2024 guidance","bullets":["Net sales $228M (-8% YoY, -5% constant currency); diluted EPS $0.86 (-9% YoY).","Reiterates FY2024 net sales outlook $850-920M and EPS $2.40-$3.00.","Greater China active customers +15% YoY, net sales +3% (+7% constant currency).","Other key markets declined: North Asia net sales -28% YoY, SE Asia -22%, Americas/Europe -12%.","Repurchased 194k shares for $9M in Q1; $62M remaining under share repurchase authorization."],"urls":{"canonical":"https://secwatch.observer/filing/0000896264-24-000138","json":"https://secwatch.observer/filing/0000896264-24-000138.json","markdown":"https://secwatch.observer/filing/0000896264-24-000138.md","text":"https://secwatch.observer/filing/0000896264-24-000138.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896264/000089626424000138/0000896264-24-000138-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896264/000089626424000138/usna-20240430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T05:14:23.859839+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e4b6fb843b8c6520eb63b957722687ebf0ecf688","claim":"USANA HEALTH SCIENCES INC reported first quarter ended March 30, 2024 results: revenue $228 million, EPS $0.86. Guidance reaffirmed.","evidence_excerpt":"Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended March 30, 2024. Key Financial & Operating Results • First quarter net sales were $228 million versus $248 million during Q1 2023, and increased 2% sequentially in constant currency. • First quarter diluted EPS was $0.86 as compared with $0.95 during Q1 2023. • Company","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/896264/000089626424000138/0000896264-24-000138-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 30, 2024"},{"label":"Revenue","value":"$228 million"},{"label":"EPS","value":"$0.86"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}